RxDoctor Payments Data

Anmar Alrabadi, MD

Nephrology · South Charleston, WVNPI 1730314998

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $833 of the $937 with a category attached, or 88.9%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $341 and has fallen 69.9% since, to $103 in 2025. That places this record below the midpoint for nephrology clinicians in WV, where the typical reported total is $740.

$937in general payments, 2019–2025

Across 45 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$210
  • Calliditas Therapeutics US Inc.$140
  • Otsuka America Pharmaceutical, Inc.$129
  • Fresenius USA Marketing, Inc.$121
  • Bayer$86
  • Vifor Pharma, Inc.$70
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$83389%
  • Education$10411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 50th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$239,880
Medicare patients
419
Services billed
1,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide26$108,084
AuryxiaFerric Citrate23$48,973
KerendiaFinerenone36$31,328
VeltassaPatiromer Calcium Sorbitex11$16,323
Sevelamer Carbonate44$10,337
JanuviaSitagliptin Phosphate12$6,476
Bumetanide106$3,570
Cinacalcet Hcl27$3,546
Gentamicin Sulfate16$591
Losartan Potassium52$572
Potassium Chloride27$494
Hydralazine Hcl32$420
Lisinopril58$398
Calcitriol38$291
Carvedilol56$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$121$108,08426 claims
Akebia Therapeutics IncAuryxia$39$48,97323 claims
BayerKerendia$86$31,32836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 nephrology providers in West Virginia.

Other nephrology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →